Agios Pharmaceuticals(AGIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AGIO Agios Pharmaceuticals

Not Yet Opened 04-06 16:00:00 EDT

34.80

-0.40

-1.14%

盘后34.80

+0.000.00%

17:18 EDT

High35.98	Low34.56	Vol1.07M
Open35.46	D1 Closing35.20	Amplitude4.05%
Mkt Cap2.03B	Tradable Cap1.79B	Total Shares58.31M
T/O37.51M	T/O Rate2.08%	Tradable Shares51.35M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AGIO","market":"US","secType":"STK","nameCN":"Agios Pharmaceuticals","latestPrice":34.8,"timestamp":1775505600000,"preClose":35.2,"halted":0,"volume":1068708,"hourTrading":{"tag":"盘后","latestPrice":34.8,"preClose":34.8,"latestTime":"17:18 EDT","volume":13276,"amount":461261.74,"timestamp":1775510311404,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.011363636363636524,"floatShares":51348506,"shares":58313812,"eps":-7.12035,"marketStatus":"Not Yet Opened","change":-0.4,"latestTime":"04-06 16:00:00 EDT","open":35.46,"high":35.98,"low":34.555,"amount":37509844.683479995,"amplitude":0.040483,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-7.12035,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1775548800000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1374638400000,"exchange":"NASDAQ","adjPreClose":35.2,"preHourTrading":{"tag":"盘前","latestPrice":35.92,"preClose":35.2,"latestTime":"09:27 EDT","volume":11,"amount":386.699995,"timestamp":1775482060068,"change":0.72,"changeRate":0.020455,"amplitude":0.034659},"postHourTrading":{"tag":"盘后","latestPrice":34.8,"preClose":34.8,"latestTime":"17:18 EDT","volume":13276,"amount":461261.74,"timestamp":1775510311404,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.651121,"impliedVol":0.5987,"impliedVolPercentile":0.436},"requestUrl":"/m/hq/s/AGIO/tweets","defaultTab":"tweets","newsList":[{"id":"2625056126","title":"Agios Pharmaceuticals Is Maintained at Neutral by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2625056126","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625056126?lang=en_us&edition=fundamental","pubTime":"2026-04-07 02:29","pubTimestamp":1775500140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AGIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 06, 2026 14:29 ET (18:29 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625671955","title":"Agios Pharmaceuticals price target raised to $36 from $31 at JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2625671955","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625671955?lang=en_us&edition=fundamental","pubTime":"2026-04-06 20:31","pubTimestamp":1775478687,"startTime":"0","endTime":"0","summary":"JPMorgan raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $36 from $31 and keeps a Neutral rating on the shares. The firm updated ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/agios-pharmaceuticals-price-target-raised-to-36-from-31-at-jpmorgan-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/agios-pharmaceuticals-price-target-raised-to-36-from-31-at-jpmorgan-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625768806","title":"Agios to report first-quarter results in conference call and webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2625768806","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625768806?lang=en_us&edition=fundamental","pubTime":"2026-04-06 19:01","pubTimestamp":1775473309,"startTime":"0","endTime":"0","summary":"Agios scheduled first-quarter 2026 financial results conference call, live webcast for April 29, 2026 at 8:00 a.m. ET.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDL531KFy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO","IE00B64PRP62.GBP","LU2095319765.USD","IE00BN0W2W23.USD","NDAQ","LU2210149790.SGD","LU2210150020.SGD","BK4139","SG9999014039.USD","IE00B3QW5Z07.USD","BK4588","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","LU0314104364.USD","SG9999014021.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4585","BK4112","SG9999014005.SGD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624506758","title":"Agios Pharmaceuticals Inc : Leerink Partners Raises Target Price to $60 From $47","url":"https://stock-news.laohu8.com/highlight/detail?id=2624506758","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624506758?lang=en_us&edition=fundamental","pubTime":"2026-04-02 20:13","pubTimestamp":1775132006,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nFWN40L0PO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624403543","title":"Agios Pharmaceuticals Is Maintained at Neutral by Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2624403543","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624403543?lang=en_us&edition=fundamental","pubTime":"2026-04-02 01:45","pubTimestamp":1775065500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AGIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 01, 2026 13:45 ET (17:45 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624594046","title":"Analysts Offer Insights on Healthcare Companies: Omeros (OMER) and Agios Pharma (AGIO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624594046","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624594046?lang=en_us&edition=fundamental","pubTime":"2026-04-01 18:20","pubTimestamp":1775038809,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Omeros (OMER) and Agios Pharma (AGIO) with bullish s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-omeros-omer-and-agios-pharma-agio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-omeros-omer-and-agios-pharma-agio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","BK4581","XLV","LU0128526141.USD","LU0029874061.USD","XBI","BK4585","BK4588","OMER","AGIO","BK4139","BK4007","LABU","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624341539","title":"Why Is Agios Pharmaceuticals Stock Surging Tuesday Afternoon?","url":"https://stock-news.laohu8.com/highlight/detail?id=2624341539","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624341539?lang=en_us&edition=fundamental","pubTime":"2026-04-01 00:39","pubTimestamp":1774975140,"startTime":"0","endTime":"0","summary":".Agios Pharmaceuticals Inc (NASDAQ: AGIO) shares are trading sharply higher Tuesday afternoon after the company said it will pursue U.S. accelerated approval for mitapivat in sickle cell disease.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/31/Closse-up-Shot-Of-White-Pills-On-Conveyo.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/31/Closse-up-Shot-Of-White-Pills-On-Conveyo.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/03/51575550/why-is-agios-pharmaceuticals-stock-surging-tuesday-afternoon","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/03/51575550/why-is-agios-pharmaceuticals-stock-surging-tuesday-afternoon","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4139","AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623533999","title":"Agios Pharmaceuticals: Mitapivat’s Accelerated Approval Path and De-Risked Sickle Cell Opportunity Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2623533999","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623533999?lang=en_us&edition=fundamental","pubTime":"2026-03-31 22:45","pubTimestamp":1774968351,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Agios Pharma today and set a price target of $65.00. Emily Bodnar has given his Buy...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/agios-pharmaceuticals-mitapivats-accelerated-approval-path-and-de-risked-sickle-cell-opportunity-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/agios-pharmaceuticals-mitapivats-accelerated-approval-path-and-de-risked-sickle-cell-opportunity-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623872885","title":"Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2623872885","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623872885?lang=en_us&edition=fundamental","pubTime":"2026-03-31 21:57","pubTimestamp":1774965420,"startTime":"0","endTime":"0","summary":"US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen for $41/share. Other gainers incl. Centessa, Annexon, Agios, Fulcrum, Scholar Rock, Alkermes, Wave Life, Perimeter Solutions, Praxis Precision, and Century Aluminum.","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/31/The-Real-Villains-No-Longer-Hide.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/31/The-Real-Villains-No-Longer-Hide.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/26/03/51568594/apellis-pharmaceuticals-centessa-pharmaceuticals-agios-pharmaceuticals-and-other-big-stocks-moving-higher-on-tuesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/03/51568594/apellis-pharmaceuticals-centessa-pharmaceuticals-agios-pharmaceuticals-and-other-big-stocks-moving-higher-on-tuesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["AGIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623586375","title":"Agios Pharmaceuticals Plans Accelerated Approval Filing for Mitapivat in Sickle Cell Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2623586375","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623586375?lang=en_us&edition=fundamental","pubTime":"2026-03-31 19:47","pubTimestamp":1774957634,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals  said Tuesday that it plans to pursue US accelerated approval for mitapivat in sickle cell disease following a pre-supplemental New Drug Application meeting with the US Food and Drug Administration.The commercial-stage company said that based on the discussions, the FDA recommended submission of a confirmatory clinical trial proposal, which Agios has already provided. The company said it expects to file an sNDA in the coming months.Results from a late-stage trial showed mitapivat has met the primary endpoint of hemoglobin response, demonstrating a statistically significant improvement versus placebo, Agios said. The drug has also reduced pain crises, though that endpoint did not reach statistical significance, the company said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623585324","title":"Agios Pharmaceuticals to pursue U.S. accelerated approval for mitapivat","url":"https://stock-news.laohu8.com/highlight/detail?id=2623585324","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623585324?lang=en_us&edition=fundamental","pubTime":"2026-03-31 19:20","pubTimestamp":1774956018,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals (AGIO) announced that it will pursue U.S. accelerated approval for mitapivat, an oral pyruvate kinase activator, in sickle ce...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/agios-pharmaceuticals-to-pursue-u-s-accelerated-approval-for-mitapivat-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/agios-pharmaceuticals-to-pursue-u-s-accelerated-approval-for-mitapivat-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623758352","title":"Agios Pharmaceuticals Inc: Plans to Submit Mitapivat Snda in Sickle Cell Disease in Coming Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2623758352","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623758352?lang=en_us&edition=fundamental","pubTime":"2026-03-31 19:01","pubTimestamp":1774954902,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nFWN40J15Q:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623583636","title":"Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-Snda Meeting With FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2623583636","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623583636?lang=en_us&edition=fundamental","pubTime":"2026-03-31 19:01","pubTimestamp":1774954902,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nFWN40J15Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617768495","title":"Agios Pharmaceuticals Principal Accounting Officer Theodore James Jr. Washburn Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2617768495","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617768495?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:08","pubTimestamp":1772744934,"startTime":"0","endTime":"0","summary":"Theodore James Jr. Washburn, Principal Accounting Officer of Agios Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agios Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 05, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL8JZgC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Agios Pharmaceuticals Principal Accounting Officer Theodore James Jr. Washburn Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617832573","title":"Agios Pharmaceuticals Is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2617832573","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617832573?lang=en_us&edition=fundamental","pubTime":"2026-03-06 03:46","pubTimestamp":1772739960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AGIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 05, 2026 14:46 ET (19:46 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616539224","title":"Agios Pharmaceuticals (AGIO) Is Down 6.3% After UAE Clears PYRUKYND As First Thalassemia Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2616539224","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616539224?lang=en_us&edition=fundamental","pubTime":"2026-03-04 18:35","pubTimestamp":1772620546,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals recently announced that the Emirates Drug Establishment in the UAE approved PYRUKYND (mitapivat) as the first and only medicine for adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia.\nThis approval, supported by global Phase 3 ENERGIZE and ENERGIZE-T data and backed by a regional partnership with NewBridge Pharmaceuticals, strengthens Agios’s push into Gulf markets for rare blood disorder treatments.\nNext, we’ll examine...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/agios-pharmaceuticals-agio-is-down-63-after-uae-clears-pyruk","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/agios-pharmaceuticals-agio-is-down-63-after-uae-clears-pyruk","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["UAE","BK4139","AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616331681","title":"Agios Pharmaceuticals Inc - Newbridge to Manage Pyrukynd Commercialization in Gulf","url":"https://stock-news.laohu8.com/highlight/detail?id=2616331681","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616331681?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:06","pubTimestamp":1772453163,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nFWN3ZQ0QF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616316833","title":"Agios’ Pyrukynd® (Mitapivat) Approved for Adults With Thalassemia in the United Arab Emirates","url":"https://stock-news.laohu8.com/highlight/detail?id=2616316833","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616316833?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:06","pubTimestamp":1772453163,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nFWN3ZQ0QF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616331867","title":"UAE Regulator Approves Agios PYRUKYND for Adult Thalassemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2616331867","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616331867?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:01","pubTimestamp":1772452898,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals Inc. said the Emirates Drug Establishment of the United Arab Emirates has approved PYRUKYND  for treating adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. The company added that NewBridge Pharmaceuticals will continue to manage commercialization of PYRUKYND in the Gulf region under a distribution agreement covering the GCC countries.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDLbX0BCx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","LU2210150020.SGD","AGIO","NDAQ","IE00B64PRP62.GBP","LU2095319765.USD","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BKPKM429.USD","SG9999014005.SGD","BK4112","SG9999014013.SGD","IE00BGHQF748.EUR","LU2210149790.SGD","SG9999014021.USD","BK4588","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611119186","title":"Agios Pharmaceuticals (AGIO) Valuation Check As Shares Trade Near Recent Levels And PYRUKYND Prospects Evolve","url":"https://stock-news.laohu8.com/highlight/detail?id=2611119186","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611119186?lang=en_us&edition=fundamental","pubTime":"2026-02-14 15:28","pubTimestamp":1771054104,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals (AGIO) has drawn investor attention after recent trading moves, with the stock last closing at $27.96. You might be weighing how its current performance lines up with the company’s underlying fundamentals.\nSee our latest analysis for Agios Pharmaceuticals.\nRecent moves around $27.96 come after a mixed stretch, with a 7 day share price return of 5.39% but a 90 day share price return of 35.95% and a 1 year total shareholder return decline of 15.83%, suggesting earlier...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/agios-pharmaceuticals-agio-valuation-check-as-shares-trade-n","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/agios-pharmaceuticals-agio-valuation-check-as-shares-trade-n","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AGIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.agios.com","stockEarnings":[{"period":"1week","weight":0.1753},{"period":"1month","weight":0.2668},{"period":"3month","weight":0.2668},{"period":"6month","weight":-0.1831},{"period":"1year","weight":0.3509},{"period":"ytd","weight":0.2785}],"compareEarnings":[{"period":"1week","weight":0.0427},{"period":"1month","weight":-0.02},{"period":"3month","weight":-0.0475},{"period":"6month","weight":-0.0211},{"period":"1year","weight":0.3041},{"period":"ytd","weight":-0.0337}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.846154,"avgChangeRate":0.040392},{"month":2,"riseRate":0.692308,"avgChangeRate":0.060535},{"month":3,"riseRate":0.538462,"avgChangeRate":-0.001595},{"month":4,"riseRate":0.615385,"avgChangeRate":0.008428},{"month":5,"riseRate":0.583333,"avgChangeRate":0.052252},{"month":6,"riseRate":0.666667,"avgChangeRate":0.045835},{"month":7,"riseRate":0.416667,"avgChangeRate":-0.012275},{"month":8,"riseRate":0.384615,"avgChangeRate":-0.041451},{"month":9,"riseRate":0.538462,"avgChangeRate":0.042929},{"month":10,"riseRate":0.384615,"avgChangeRate":-0.007074},{"month":11,"riseRate":0.615385,"avgChangeRate":0.033339},{"month":12,"riseRate":0.384615,"avgChangeRate":-0.051358}],"exchange":"NASDAQ","name":"Agios Pharmaceuticals","nameEN":"Agios Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Agios Pharmaceuticals(AGIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Agios Pharmaceuticals(AGIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Agios Pharmaceuticals,AGIO,Agios Pharmaceuticals股票,Agios Pharmaceuticals股票老虎,Agios Pharmaceuticals股票老虎国际,Agios Pharmaceuticals行情,Agios Pharmaceuticals股票行情,Agios Pharmaceuticals股价,Agios Pharmaceuticals股市,Agios Pharmaceuticals股票价格,Agios Pharmaceuticals股票交易,Agios Pharmaceuticals股票购买,Agios Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Agios Pharmaceuticals(AGIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Agios Pharmaceuticals(AGIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}